New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 4, 2006, Pages 341-351

  Villeval, Jean Luc ^a,b   James, Chloé ^c   Pisani, Didier F ^a,b   Casadevall, Nicole ^a,d   Vainchenker, William ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

^d HÔTEL DIEU   (France)

Author keywords

Diagnosis; Diversity; JAK2 V617F; Myeloproliferative disorders; Prognosis; Treatment

Indexed keywords

BCR ABL PROTEIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GENOMIC DNA; GENOMIC RNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE; PROTEIN KINASE B; SOMATOMEDIN C; STAT5 PROTEIN; STEM CELL FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING; THROMBOPOIETIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLEEDING; BURST FORMING UNIT E; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; CLONAL VARIATION; COLONY FORMING UNIT E; DISEASE CLASSIFICATION; DISEASE COURSE; EXTRAMEDULLARY HEMATOPOIESIS; GENE MUTATION; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; HYPEREOSINOPHILIC SYNDROME; LEUKEMOGENESIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPLENOMEGALY; SYSTEMATIC REVIEW; SYSTEMIC MASTOCYTOSIS; THROMBOCYTHEMIA; THROMBOSIS; WORLD HEALTH ORGANIZATION;

AMINO ACID SUBSTITUTION; CLINICAL TRIALS; HUMANS; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; PROSPECTIVE STUDIES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 33745686457     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-942755     Document Type: Article

References (69)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372-375
2. Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 2004;41:1-5
3. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005;11:548-554
4. Vardiman JW, Harris NL, Brunning RD. The world health organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302
5. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976;295:913-916
6. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981;58:916-919
7. el-Kassar N, Hetet G, Briere J, Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets. Blood 1997;89:128-134
8. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999;93:417-424
9. Prchal JF, Axelrad AA. Letter: bone-marrow responses in polycythemia vera. N Engl J Med 1974;290:1382
10. Pahl HL. PRV-1 mRNA expression and other molecular markers in polycythemia rubra vera. Curr Hematol Rep 2003;2:231-236
11. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998;338:572-580
12. Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004;32:179-187
13. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148
14. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790
15. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061
16. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397
17. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788-22792
18. Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005;23:6285-6295
19. De Keersmaecker K, Cools J. Chronic myeloproliferative disorders: a tyrosine kinase tale. Leukemia 2006;20:200-205
20. Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of JAK2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 2003;14:1448-1459
21. Schindler CW. Series introduction. JAK-STAT signaling in human disease. J Clin Invest 2002;109:1133-1137
22. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006;107:4274-4281
23. Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 2005;102:18962-18967
24. Staerk J, Kallin A, Demoulin JB, Vainchenker W, Constantinescu SN. JAK1 and TYK2 activation by the homologous polycythemia vera JAK2 V617F mutation: Cross-talk with igf1 receptor. J Biol Chem 2005;280:41893-41899
25. Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1997;90: 4369-4383
26. Tefferi A, Lasho TL, Gilliland G. JAK2 mutations in myeloproliferative disorders. N Engl J Med 2005;353:1416-1417
27. 26a. Lacout C, Pisani DF, Tulliez M, et al. JAK2 V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006 May 2; [Epub ahead of print]
28. Spivak JL. Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry. Semin Hematol 2003;40: 1-5
29. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Hematology (Am Soc Hematol Educ Program) 2005;533-537
30. Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005;19:1847-1849
31. Levine RL, Belisle C, Wadleigh M, et al. X-inactivation based clonality analysis and quantitative JAK2V617F assessment reveals a strong association between clonality and JAK2V617F in pv but not et/mmm, and identifies a subset of JAK2V617F negative et and mmm patients with clonal hematopoiesis. Blood 2006. In press
32. Tefferi A, Pardanani A. Mutation screening for JAK2(V617F): when to order the test and how to interpret the results. Leuk Res 2006. In press
33. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-1953
34. Tefferi A, Lasho TL, Schwager SM, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006;106:631-635
35. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation and constitutive mobilization of cd34-positive cells into peripheral blood in myeloproliferative disorders. Blood 2005. In press
36. Zhao ZJ, Vainchenker W, Krantz SB, Casadevall N, Constantinescu SN. Role of tyrosine kinases and phosphatases in polycythemia vera. Semin Hematol 2005;42:221-229
37. Wormald S, Hilton DJ. Inhibitors of cytokine signal transduction. J Biol Chem 2004;279:821-824
38. Moliterno AR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll RG, Spivak JL. Mp1 Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci USA 2004;101:11444-11447
39. Huang LJ, Constantinescu SN, Lodish HF. The n-terminal domain of janus kinase 2 is required for golgi processing and cell surface expression of erythropoietin receptor. Mol Cell 2001;8:1327-1338
40. Royer Y, Staerk J, Costuleanu M, Courtoy PJ, Constantinescu SN. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem 2005;280:27251-27261
41. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006;91:169-175
42. Campbell PJ, Griesshammer M, Dohner K, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006;107:2098-2100
43. Bench AJ, Pahl HL. Chromosomal abnormalities and molecular markers in myeloproliferative disorders. Semin Hematol 2005;42:196-205
44. Skoda R, Prchal JT. Lessons from familial myeloproliferative disorders. Semin Hematol 2005;42:266-273
45. 43a. Bellanné-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006 Mar 14; [Epub ahead of print]
46. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006;20:350-353
47. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-2168
48. Campbell PJ, Scott LM, Baxter EJ, Bench AJ, Green AR, Erber WN. Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders. Methods Mol Med 2006;125:253-264
49. Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002;76:133-145
50. Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative disorders-current diagnostic approach. Semin Hematol 2005;42:184-195
51. Thiele J, Kvasnicka HM. A critical reappraisal of the who classification of the chronic myeloproliferative disorders. Leuk Lymphoma 2006;47:381-396
52. Goerttler PS, Steimle C, Marz E, et al. The JAK2V617F mutation, prv-1 overexpression, and eec formation define a similar cohort of mpd patients. Blood 2005;106:2862-2864
53. Bellosillo B, Besses C, Florensa L, Sole F, Serrano S. JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among ph-negative chronic myeloproliferative disorders. Leukemia 2006;20:736
54. Tefferi A, Sirhan S, Lasho TL, et al. Concomitant neutrophil JAK2 mutation screening and prv-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol 2005;131:166-171
55. Goerttler PS, Kreutz C, Donauer J, et al. Gene expression profiling in polycythaemia vera: overexpression of transcription factor nf-e2. Br J Haematol 2005;129:138-150
56. Kralovics R, Teo SS, Buser AS, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of JAK2. Blood 2005;106: 3374-3376
57. Jelinek J, Old Y, Gharibyan V, et al. JAK2 mutation 1849g > t is rare in acute leukemias but can be found in cmml, Philadelphia chromosome-negative cml, and megakaryocytic leukemia. Blood 2005;106:3370-3373
58. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005;131:208-213
59. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-187
60. Jones AV, Silver RT, Waghorn K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 2005. In press
61. Lucet IS, Fantino E, Styles M, et al. The structural basis of janus kinase 2 inhibition by a potent and specific pan-janus kinase inhibitor. Blood 2006;107:176-183
62. Lacronique V, Boureux A, Monni R, et al. Transforming properties of chimeric tel-jak proteins in ba/f3 cells. Blood 2000;95:2076-2083
63. Sternberg DW, Gilliland DG. The role of signal transducer and activator of transcription factors in leukemogenesis. J Clin Oncol 2004;22:361-371
64. Sandberg EM, Wallace TA, Godeny MD, Vonderlinden D, Sayeski PP. JAK2 tyrosine kinase: a true jak of all trades? Cell Biochem Biophys 2004;41:207-232
65. Wagner KU, Krempler A, Triplett AA, et al. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in JAK2 conditional knockout mice. Mol Cell Biol 2004;24:5510-5520
66. Parganas E, Wang D, Stravopodis D, et al. JAK2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93:385-395
67. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. JAK2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998;93:397-409
68. Komura E, Chagraoui H, Mansat de Mas V, et al. Spontaneous STATS activation induces growth factor independence in idiopathic myelofibrosis: Possible relationship with fkbp51 overexpression. Exp Hematol 2003;31: 622-630
69. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005;23:8520-8530